Rutgers Cancer Institute of New Jersey receives $25 million for Cancer Immunology and Metabolism Center of Excellence

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A $25 million anonymous philanthropic gift to Rutgers Cancer Institute of New Jersey will provide groundbreaking support for the Cancer Immunology and Metabolism Center of Excellence.

This donation will support faculty recruitment, shared resource development, and cancer research to help scientists better understand the human immune response to cancer and develop the foundation for new treatments, or make existing therapies more effective.

With the support of this gift, investigators will accelerate laboratory discoveries pertaining to these disciplines into clinical treatments through more effective and efficiently designed clinical trials. These trials would be offered in conjunction with other cancer centers and collaborators such as the Big Ten Cancer Research Consortium, and made accessible to patients at RWJBarnabas Health facilities across the state.

In collaboration with its research consortium partner Princeton University, Rutgers Cancer Institute is considered an authority in the study of metabolism.

The gift also supports the recruitment of a co-director to lead the center along with Eileen White, deputy director of Rutgers Cancer Institute and chief scientific officer. Following a nationwide search, Christian Hinrichs, an expert in cancer immunology and immunotherapy, was recruited from NCI. He will begin his new role in January.

Additional new faculty to the center also will be supported through this gift.

The gift is part of an overall $50 million fundraising campaign, for which the aim is to secure an additional $25 million to fuel the work of the Cancer Immunology and Metabolism Center of Excellence.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login